Life sciences supply chains are among the most complex in the world. Every day, supply chain leaders must balance shifting demand, constrained supply, and strict regulatory requirements, all while ensuring patients get the medications they need. The margin for error is small, and disconnected, stage-by-stage planning just cannot keep up.
The companies pulling ahead are closing that gap with end-to-end, reality-based supply chain planning, connecting demand, manufacturing, quality control, and clinical pipelines into one synchronized view grounded in what's actually happening on the plant floor, not last quarter's forecast.
This e-book breaks down the five planning challenges that define pharmaceutical and biopharma supply chains, with real-world examples (from flu vaccine demand surges to cross-continental production shifts) and shows how OMP's Unison Planning™ for Life Sciences empowers life sciences companies to stay agile, compliant, and efficient while safeguarding patient supply.
You'll learn how to:
- Manage demand variability across complex, multi-stage pharma and biopharma supply chains
- Reduce the impact of supply variability, yield fluctuation, and regulatory complexity
- Maintain high service levels without inflating inventory or straining production efficiency
- Navigate FDA, EMA, and other regulatory constraints while staying flexible to change
- Plan clinical pipelines and long-term capacity with confidence, even when ±90% of pipeline products never reach approval
You'll also discover how Unison Planning's reality-based digital twin, AI, scenario planning, and characteristics-based modeling and end-to-end visibility across strategic, tactical, and operational horizons help leading biopharma and animal health companies, including Roche, Johnson & Johnson, AstraZeneca, and Bayer, turn planning complexity into a competitive advantage.
If your team is stuck firefighting instead of staying ahead, this guide shows the path forward.
Download the e-book now and see how end-to-end, reality-based planning keeps top pharma supply chains ahead.